Our group studies the role of large-scale chromosomal changes known as copy number alterations (CNA) in pancreatic ductal adenocarcinoma (PDAC). We combine state-of-the-art genomic engineering strategies with in vivo models of PDAC to uncover the mechanisms by which NACs enable cancer cells to spread and resist therapies.

We are particularly interested in the role of these alterations in immune surveillance, tumor heterogeneity and cancer genome evolution. Our long-term goal is to understand the complex biology of CNAs to identify new therapeutic strategies that target PDAC cells with these chromosomal aberrations.